When does Winrevair’s patent expire?
Public information on the exact expiration date isn’t provided here. Patent life depends on multiple factors, including the specific patent(s) covering Winrevair, filing dates, claim scope, and any adjustments or exclusivity periods that apply in the relevant country.
Which patents matter for Winrevair (and why the date can differ)?
For drugs like Winrevair (vixarelimab), “patent expiry” can mean different things:
- Expiration of the first issued patent covering the product
- Expiration of later “secondary” patents (e.g., specific formulations, dosing regimens, manufacturing processes, or additional therapeutic claims)
- Expiration of exclusivity protections that can delay generic or biosimilar entry even after a patent expires
Those protections can have different timelines, so the earliest expiration date for one patent may not match the effective market-entry timing.
How to find the exact expiration date
To get the precise date, you typically need to look up Winrevair in the patent and regulatory listings for the country of interest:
- The U.S. FDA’s Orange Book listings (for drug-product exclusivities and relevant patents)
- Patent registries or legal status databases that show each specific patent’s expiration and any term adjustments
If you tell me which country you care about (U.S., EU, UK, etc.) and whether you mean “earliest patent expiry” or “latest barrier to competition,” I can narrow down what to check and how to interpret it.